Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL16485958 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27648704 | 0.97 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL28023088 | 0.89 | SLC7A5 (0.63) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL10429981 | 0.89 | SLC7A5 (0.63) | SLC7A5PTGS1ALPIPKMXIAP | |
| D-Phenylalanine SCHEMBL20267959 | 0.88 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL28341547 | 0.88 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL20267852 | 0.88 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL20267856 | 0.88 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL155762 | 0.87 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL147621 | 0.87 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4533506-A | Resolution of amino acids | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1985-08-06 | — | — | US | claimed |
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2024-05-09 | — | — | US | disclosed |
| US-10786497-B2 | Discrete PEG constructs | EQUIP, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200230133-A1 | Discrete PEG Constructs | EqIP, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-20150065711-A1 | Discrete PEG Constructs | EQUIP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015023979-A1 | DISCRETE PEG CONSTRUCTS | EQUIP, LLC (US) | 2015-02-19 | — | — | WO | disclosed |
| US-4691008-A | COUPLING A URETHANE-BLOCKED TRIPEPTIDE AND A PEPTIDE WITH A FREE AMINE USING A CONDENSATION AGENT | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | disclosed |
| US-4533506-A | Resolution of amino acids | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1985-08-06 | — | — | US | disclosed |
| US-4390722-A | CRYSTALLIZATION FROM SUPERSATURATED SOLUTION USING AMINO ACID AS AS CRYSTAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | MUC1, EGFR, LNPEP | EGFR 2/4885SLC7A5 1842/4885PTGS1 4590/4885 |
| US-20150065711-A1 | Discrete PEG Constructs | MUC1, EGFR, LNPEP | EGFR 2/4885SLC7A5 1842/4885PTGS1 4590/4885 |
| US-10786497-B2 | Discrete PEG constructs | MUC1, EGFR, LNPEP | EGFR 2/4885SLC7A5 1842/4885PTGS1 4590/4885 |
| US-20200230133-A1 | Discrete PEG Constructs | MUC1, EGFR, LNPEP | EGFR 2/4885SLC7A5 1842/4885PTGS1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.